glp-1 drugs cancer Dr Does Using GLP-1 Drugs, Like
Description
Type 2 diabetes segment contributed the largest market share in 2024
Tong G, Peng T, Chen Y, Sha L, Dai H, Xiang Y, et al
In people with obesity, 36 weeks of orforglipron (doses ranging from 12 to 45 mg in a phase 2 trial) resulted in a dose-dependent WL up to 14.7% compared to 2.3% with placebo, with concomitant improvement in cardiometabolic risk factors (Table 2) [25]
Beyond this period, simply continue with your regular schedule as advised by our healthcare professionals
Roger S
